<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170193</url>
  </required_header>
  <id_info>
    <org_study_id>20160338</org_study_id>
    <nct_id>NCT03170193</nct_id>
  </id_info>
  <brief_title>AMG 529 First in Human Study</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety and tolerability of AMG 529 following single, ascending doses
      administered subcutaneously (SC) or intravenously (IV) in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">November 17, 2017</completion_date>
  <primary_completion_date type="Actual">November 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Within each dose cohort participants were randomized in a 3:1 ratio to receive either AMG 529 or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From first dose up to 30 days for participants assigned to the 21 mg or 70 mg dose cohorts and up to 57 days for participants assigned to the 210 mg, 420 mg, or 700 mg dose cohorts.</time_frame>
    <description>Determination of the severity of adverse events was according to the following: grade 1 = mild (eg, asymptomatic or mild symptoms); grade 2 = moderate (eg, minimal intervention indicated or interferes with activity); grade 3 = severe (eg, medically significant but not immediately life-threatening, prevents daily activity, or requires treatment); grade 4 = life-threatening (ie, refers to an event in which the participant was, in the view of the investigator, at risk of death at the time of the event); and grade 5 = fatal.
A serious adverse event was defined as an adverse event that met at least 1 of the following criteria:
fatal
life threatening
required in patient hospitalization or prolongation of existing hospitalization
resulted in persistent or significant disability/incapacity
congenital anomaly/birth defect
other medically important serious event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of AMG 529</measure>
    <time_frame>Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of AMG 529</measure>
    <time_frame>Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time 0 to the Last Quantifiable Concentration (AUClast) for AMG 529</measure>
    <time_frame>Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Alkaline Phosphatase Concentration Over Time</measure>
    <time_frame>Baseline and days 3, 8, and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol Concentration Over Time</measure>
    <time_frame>Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration Over Time</measure>
    <time_frame>Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) Concentration Over Time</measure>
    <time_frame>Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides Concentration Over Time</measure>
    <time_frame>Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cardiovascular</condition>
  <arm_group>
    <arm_group_label>AMG 529</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 529</intervention_name>
    <description>Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection</description>
    <arm_group_label>AMG 529</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single doses of matching placebo by SC or IV injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy men and women ≥ 18 to ≤ 55 years old with no history or evidence of clinically
             relevant medical disorders

          2. Body mass index (BMI) between 18 and 32 kg/m², inclusive, at screening

          3. Women must be of non-reproductive potential as defined in protocol

          4. Other inclusion criteria may apply

        Exclusion Criteria:

          1. Currently receiving treatment in another investigational device or drug study, or less
             than 30 days or 5 half-lives (whichever is longer), since ending treatment on another
             investigational device or drug study(s) prior to receiving the first dose of
             investigational product

          2. Women who are lactating/breastfeeding or who plan to breastfeed while on study through
             90 days after receiving the dose of investigational product

          3. Men with partners who are pregnant or planning to become pregnant while the subject is
             on study through 90 days after receiving the dose of investigational product

          4. Positive pregnancy test at screening or day -1

          5. Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>April 12, 2019</results_first_submitted>
  <results_first_submitted_qc>April 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03170193/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03170193/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at a single center in the United States. Participants were enrolled from 15 May 2017 to 18 September 2017.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into one of six dose cohorts. Within each cohort participants were randomized in a ratio of 3:1 to receive AMG 529 or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
        </group>
        <group group_id="P2">
          <title>AMG 529 21 mg SC</title>
          <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
        </group>
        <group group_id="P3">
          <title>AMG 529 70 mg SC</title>
          <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="P4">
          <title>AMG 529 210 mg SC</title>
          <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="P5">
          <title>AMG 529 420 mg SC</title>
          <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="P6">
          <title>AMG 529 700 mg SC</title>
          <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="P7">
          <title>AMG 529 70 mg IV</title>
          <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
        </group>
        <group group_id="B2">
          <title>AMG 529 21 mg SC</title>
          <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
        </group>
        <group group_id="B3">
          <title>AMG 529 70 mg SC</title>
          <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="B4">
          <title>AMG 529 210 mg SC</title>
          <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="B5">
          <title>AMG 529 420 mg SC</title>
          <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="B6">
          <title>AMG 529 700 mg SC</title>
          <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="B7">
          <title>AMG 529 70 mg IV</title>
          <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="10.5"/>
                    <measurement group_id="B2" value="33.5" spread="12.5"/>
                    <measurement group_id="B3" value="32.3" spread="11.6"/>
                    <measurement group_id="B4" value="45.2" spread="11.6"/>
                    <measurement group_id="B5" value="35.0" spread="11.0"/>
                    <measurement group_id="B6" value="36.5" spread="9.6"/>
                    <measurement group_id="B7" value="34.7" spread="12.7"/>
                    <measurement group_id="B8" value="36.1" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>Determination of the severity of adverse events was according to the following: grade 1 = mild (eg, asymptomatic or mild symptoms); grade 2 = moderate (eg, minimal intervention indicated or interferes with activity); grade 3 = severe (eg, medically significant but not immediately life-threatening, prevents daily activity, or requires treatment); grade 4 = life-threatening (ie, refers to an event in which the participant was, in the view of the investigator, at risk of death at the time of the event); and grade 5 = fatal.
A serious adverse event was defined as an adverse event that met at least 1 of the following criteria:
fatal
life threatening
required in patient hospitalization or prolongation of existing hospitalization
resulted in persistent or significant disability/incapacity
congenital anomaly/birth defect
other medically important serious event.</description>
        <time_frame>From first dose up to 30 days for participants assigned to the 21 mg or 70 mg dose cohorts and up to 57 days for participants assigned to the 210 mg, 420 mg, or 700 mg dose cohorts.</time_frame>
        <population>Randomized participants who received at least 1 dose of AMG 529 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O7">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>Determination of the severity of adverse events was according to the following: grade 1 = mild (eg, asymptomatic or mild symptoms); grade 2 = moderate (eg, minimal intervention indicated or interferes with activity); grade 3 = severe (eg, medically significant but not immediately life-threatening, prevents daily activity, or requires treatment); grade 4 = life-threatening (ie, refers to an event in which the participant was, in the view of the investigator, at risk of death at the time of the event); and grade 5 = fatal.
A serious adverse event was defined as an adverse event that met at least 1 of the following criteria:
fatal
life threatening
required in patient hospitalization or prolongation of existing hospitalization
resulted in persistent or significant disability/incapacity
congenital anomaly/birth defect
other medically important serious event.</description>
          <population>Randomized participants who received at least 1 dose of AMG 529 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events Grade ≥ 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events Grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events Grade ≥ 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of AMG 529</title>
        <time_frame>Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.</time_frame>
        <population>Participants who received AMG 529 for whom at least 1 PK parameter or endpoint was reliably estimated. Four participants were excluded from PK analyses as their profiles had &lt; 2 samples that were above the lower limit of quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of AMG 529</title>
          <population>Participants who received AMG 529 for whom at least 1 PK parameter or endpoint was reliably estimated. Four participants were excluded from PK analyses as their profiles had &lt; 2 samples that were above the lower limit of quantification.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.90" spread="1.73"/>
                    <measurement group_id="O2" value="23.8" spread="13.4"/>
                    <measurement group_id="O3" value="2010" spread="3120"/>
                    <measurement group_id="O4" value="9370" spread="10800"/>
                    <measurement group_id="O5" value="35600" spread="32700"/>
                    <measurement group_id="O6" value="3460" spread="4430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Concentration (Tmax) of AMG 529</title>
        <time_frame>Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.</time_frame>
        <population>Participants who received AMG 529 for whom at least 1 PK parameter or endpoint was reliably estimated. Four participants were excluded from PK analyses as their profiles had &lt; 2 samples that were above the lower limit of quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) of AMG 529</title>
          <population>Participants who received AMG 529 for whom at least 1 PK parameter or endpoint was reliably estimated. Four participants were excluded from PK analyses as their profiles had &lt; 2 samples that were above the lower limit of quantification.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O2" value="5.8" lower_limit="5.8" upper_limit="5.8"/>
                    <measurement group_id="O3" value="72" lower_limit="24" upper_limit="72"/>
                    <measurement group_id="O4" value="72" lower_limit="24" upper_limit="72"/>
                    <measurement group_id="O5" value="96" lower_limit="36" upper_limit="170"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.5" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time 0 to the Last Quantifiable Concentration (AUClast) for AMG 529</title>
        <time_frame>Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts.</time_frame>
        <population>Participants who received AMG 529 for whom at least 1 PK parameter or endpoint was reliably estimated. Four participants were excluded from PK analyses as their profiles had &lt; 2 samples that were above the lower limit of quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to the Last Quantifiable Concentration (AUClast) for AMG 529</title>
          <population>Participants who received AMG 529 for whom at least 1 PK parameter or endpoint was reliably estimated. Four participants were excluded from PK analyses as their profiles had &lt; 2 samples that were above the lower limit of quantification.</population>
          <units>days*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="2.90"/>
                    <measurement group_id="O2" value="46.0" spread="47.4"/>
                    <measurement group_id="O3" value="5370" spread="8520"/>
                    <measurement group_id="O4" value="41800" spread="51000"/>
                    <measurement group_id="O5" value="289000" spread="330000"/>
                    <measurement group_id="O6" value="766" spread="1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Alkaline Phosphatase Concentration Over Time</title>
        <time_frame>Baseline and days 3, 8, and 30</time_frame>
        <population>Participants who received at least 1 dose of study drug and with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O7">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Alkaline Phosphatase Concentration Over Time</title>
          <population>Participants who received at least 1 dose of study drug and with available data at each time point</population>
          <units>units/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" spread="13.8"/>
                    <measurement group_id="O2" value="69.0" spread="21.2"/>
                    <measurement group_id="O3" value="56.0" spread="10.8"/>
                    <measurement group_id="O4" value="68.0" spread="12.2"/>
                    <measurement group_id="O5" value="57.7" spread="9.0"/>
                    <measurement group_id="O6" value="57.5" spread="18.0"/>
                    <measurement group_id="O7" value="58.0" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.2"/>
                    <measurement group_id="O2" value="4.7" spread="4.7"/>
                    <measurement group_id="O3" value="7.0" spread="7.0"/>
                    <measurement group_id="O4" value="57.0" spread="51.7"/>
                    <measurement group_id="O5" value="76.7" spread="76.9"/>
                    <measurement group_id="O6" value="88.2" spread="33.5"/>
                    <measurement group_id="O7" value="28.7" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="6.0"/>
                    <measurement group_id="O2" value="3.2" spread="7.5"/>
                    <measurement group_id="O3" value="17.0" spread="10.4"/>
                    <measurement group_id="O4" value="102.6" spread="70.8"/>
                    <measurement group_id="O5" value="199.3" spread="256.1"/>
                    <measurement group_id="O6" value="155.8" spread="34.8"/>
                    <measurement group_id="O7" value="8.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="8.5"/>
                    <measurement group_id="O2" value="-1.4" spread="4.0"/>
                    <measurement group_id="O3" value="1.8" spread="5.3"/>
                    <measurement group_id="O4" value="-0.8" spread="4.0"/>
                    <measurement group_id="O5" value="11.8" spread="5.9"/>
                    <measurement group_id="O6" value="14.6" spread="6.5"/>
                    <measurement group_id="O7" value="2.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol Concentration Over Time</title>
        <time_frame>Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts.</time_frame>
        <population>Randomized participants who received study drug with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O7">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol Concentration Over Time</title>
          <population>Randomized participants who received study drug with available data at each time point.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5817" spread="0.8204"/>
                    <measurement group_id="O2" value="5.3567" spread="0.9662"/>
                    <measurement group_id="O3" value="4.8383" spread="1.0789"/>
                    <measurement group_id="O4" value="5.3417" spread="0.9771"/>
                    <measurement group_id="O5" value="4.2483" spread="0.6335"/>
                    <measurement group_id="O6" value="4.8533" spread="0.8125"/>
                    <measurement group_id="O7" value="5.0633" spread="1.5937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0692" spread="0.2381"/>
                    <measurement group_id="O2" value="-0.1583" spread="0.1347"/>
                    <measurement group_id="O3" value="-0.0200" spread="0.2254"/>
                    <measurement group_id="O4" value="0.0800" spread="0.2224"/>
                    <measurement group_id="O5" value="0.1617" spread="0.2375"/>
                    <measurement group_id="O6" value="0.2350" spread="0.1299"/>
                    <measurement group_id="O7" value="0.3400" spread="0.3428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0867" spread="0.4151"/>
                    <measurement group_id="O2" value="-0.3317" spread="0.1997"/>
                    <measurement group_id="O3" value="-0.3533" spread="0.3426"/>
                    <measurement group_id="O4" value="-0.2520" spread="0.6208"/>
                    <measurement group_id="O5" value="-0.3267" spread="0.3140"/>
                    <measurement group_id="O6" value="-0.1667" spread="0.2614"/>
                    <measurement group_id="O7" value="0.3350" spread="0.5461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4625" spread="0.4110"/>
                    <measurement group_id="O2" value="-1.0620" spread="0.5976"/>
                    <measurement group_id="O3" value="-0.6933" spread="0.4763"/>
                    <measurement group_id="O4" value="-0.6700" spread="0.5770"/>
                    <measurement group_id="O5" value="-0.8500" spread="0.6339"/>
                    <measurement group_id="O6" value="-0.7600" spread="0.5306"/>
                    <measurement group_id="O7" value="-0.0340" spread="0.8344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0300" spread="0.5567"/>
                    <measurement group_id="O2" value="-0.7480" spread="0.8825"/>
                    <measurement group_id="O3" value="-0.2550" spread="0.5021"/>
                    <measurement group_id="O4" value="-0.1640" spread="0.3092"/>
                    <measurement group_id="O5" value="-0.2183" spread="0.4100"/>
                    <measurement group_id="O6" value="-0.2040" spread="0.5358"/>
                    <measurement group_id="O7" value="-0.3200" spread="0.9193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0936" spread="0.7880"/>
                    <measurement group_id="O2" value="-0.6780" spread="0.3467"/>
                    <measurement group_id="O3" value="-0.1933" spread="0.4376"/>
                    <measurement group_id="O4" value="0.1300" spread="0.0919"/>
                    <measurement group_id="O5" value="0.2583" spread="0.4088"/>
                    <measurement group_id="O6" value="0.1380" spread="0.4964"/>
                    <measurement group_id="O7" value="-0.1140" spread="0.9209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1840" spread="0.7451"/>
                    <measurement group_id="O4" value="0.5120" spread="0.8889"/>
                    <measurement group_id="O5" value="0.2383" spread="0.4896"/>
                    <measurement group_id="O6" value="-0.0033" spread="0.9705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration Over Time</title>
        <time_frame>Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts.</time_frame>
        <population>Randomized participants who received study drug with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O7">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration Over Time</title>
          <population>Randomized participants who received study drug with available data at each time point.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8317" spread="0.8071"/>
                    <measurement group_id="O2" value="3.2683" spread="1.0026"/>
                    <measurement group_id="O3" value="2.8400" spread="0.7687"/>
                    <measurement group_id="O4" value="3.4017" spread="1.2875"/>
                    <measurement group_id="O5" value="2.4633" spread="0.5727"/>
                    <measurement group_id="O6" value="3.2267" spread="0.7112"/>
                    <measurement group_id="O7" value="3.1583" spread="1.1382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1608" spread="0.2423"/>
                    <measurement group_id="O2" value="0.1383" spread="0.3271"/>
                    <measurement group_id="O3" value="0.2150" spread="0.1571"/>
                    <measurement group_id="O4" value="-0.0867" spread="0.3280"/>
                    <measurement group_id="O5" value="0.2650" spread="0.1401"/>
                    <measurement group_id="O6" value="0.3350" spread="0.2482"/>
                    <measurement group_id="O7" value="0.3350" spread="0.2874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1400" spread="0.2992"/>
                    <measurement group_id="O2" value="0.0417" spread="0.3547"/>
                    <measurement group_id="O3" value="0.1050" spread="0.1549"/>
                    <measurement group_id="O4" value="-0.5860" spread="0.5180"/>
                    <measurement group_id="O5" value="-0.0967" spread="0.2708"/>
                    <measurement group_id="O6" value="-0.0967" spread="0.1975"/>
                    <measurement group_id="O7" value="0.1650" spread="0.5853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3367" spread="0.4298"/>
                    <measurement group_id="O2" value="-0.7600" spread="0.4464"/>
                    <measurement group_id="O3" value="-0.3900" spread="0.2912"/>
                    <measurement group_id="O4" value="-0.7920" spread="0.4873"/>
                    <measurement group_id="O5" value="-0.7333" spread="0.5000"/>
                    <measurement group_id="O6" value="-0.5850" spread="0.2204"/>
                    <measurement group_id="O7" value="-0.0520" spread="0.5955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0117" spread="0.4577"/>
                    <measurement group_id="O2" value="-0.5240" spread="0.8043"/>
                    <measurement group_id="O3" value="-0.0600" spread="0.3205"/>
                    <measurement group_id="O4" value="-0.2860" spread="0.4116"/>
                    <measurement group_id="O5" value="-0.3517" spread="0.3969"/>
                    <measurement group_id="O6" value="-0.3960" spread="0.1521"/>
                    <measurement group_id="O7" value="-0.2780" spread="0.7706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1018" spread="0.6698"/>
                    <measurement group_id="O2" value="-0.4260" spread="0.4258"/>
                    <measurement group_id="O3" value="-0.0767" spread="0.4002"/>
                    <measurement group_id="O4" value="-0.4020" spread="0.4773"/>
                    <measurement group_id="O5" value="0.2667" spread="0.3768"/>
                    <measurement group_id="O6" value="-0.0740" spread="0.4999"/>
                    <measurement group_id="O7" value="-0.2680" spread="0.9091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0500" spread="0.7559"/>
                    <measurement group_id="O4" value="0.0520" spread="0.6514"/>
                    <measurement group_id="O5" value="0.1283" spread="0.3075"/>
                    <measurement group_id="O6" value="-0.1617" spread="0.8583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) Concentration Over Time</title>
        <time_frame>Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts.</time_frame>
        <population>Randomized participants who received study drug with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O7">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) Concentration Over Time</title>
          <population>Randomized participants who received study drug with available data at each time point.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1775" spread="0.2932"/>
                    <measurement group_id="O2" value="1.3783" spread="0.2928"/>
                    <measurement group_id="O3" value="1.3950" spread="0.2626"/>
                    <measurement group_id="O4" value="1.4133" spread="0.4968"/>
                    <measurement group_id="O5" value="1.2633" spread="0.2202"/>
                    <measurement group_id="O6" value="1.0700" spread="0.4527"/>
                    <measurement group_id="O7" value="1.4417" spread="0.5517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0592" spread="0.1094"/>
                    <measurement group_id="O2" value="-0.0100" spread="0.1092"/>
                    <measurement group_id="O3" value="-0.1267" spread="0.0935"/>
                    <measurement group_id="O4" value="0.0417" spread="0.1032"/>
                    <measurement group_id="O5" value="-0.0600" spread="0.1373"/>
                    <measurement group_id="O6" value="0.0783" spread="0.0981"/>
                    <measurement group_id="O7" value="-0.0383" spread="0.1118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0975" spread="0.1096"/>
                    <measurement group_id="O2" value="-0.1617" spread="0.1254"/>
                    <measurement group_id="O3" value="-0.2083" spread="0.1430"/>
                    <measurement group_id="O4" value="-0.0980" spread="0.1417"/>
                    <measurement group_id="O5" value="-0.1100" spread="0.2028"/>
                    <measurement group_id="O6" value="0.0350" spread="0.1816"/>
                    <measurement group_id="O7" value="-0.0767" spread="0.1402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0133" spread="0.1224"/>
                    <measurement group_id="O2" value="-0.2080" spread="0.1854"/>
                    <measurement group_id="O3" value="-0.1600" spread="0.1689"/>
                    <measurement group_id="O4" value="-0.0960" spread="0.1318"/>
                    <measurement group_id="O5" value="-0.0800" spread="0.0812"/>
                    <measurement group_id="O6" value="0.0475" spread="0.0768"/>
                    <measurement group_id="O7" value="-0.0060" spread="0.1809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0208" spread="0.1468"/>
                    <measurement group_id="O2" value="-0.0580" spread="0.1644"/>
                    <measurement group_id="O3" value="-0.0417" spread="0.1815"/>
                    <measurement group_id="O4" value="0.0220" spread="0.1026"/>
                    <measurement group_id="O5" value="0.0583" spread="0.1533"/>
                    <measurement group_id="O6" value="0.2860" spread="0.1704"/>
                    <measurement group_id="O7" value="0.0320" spread="0.1583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0473" spread="0.1769"/>
                    <measurement group_id="O2" value="-0.0760" spread="0.0853"/>
                    <measurement group_id="O3" value="-0.0400" spread="0.3107"/>
                    <measurement group_id="O4" value="0.1380" spread="0.1644"/>
                    <measurement group_id="O5" value="0.0667" spread="0.2060"/>
                    <measurement group_id="O6" value="0.2480" spread="0.0944"/>
                    <measurement group_id="O7" value="0.1340" spread="0.1396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0540" spread="0.1549"/>
                    <measurement group_id="O4" value="0.1160" spread="0.1595"/>
                    <measurement group_id="O5" value="0.1483" spread="0.1113"/>
                    <measurement group_id="O6" value="0.2633" spread="0.2470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides Concentration Over Time</title>
        <time_frame>Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts.</time_frame>
        <population>Randomized participants who received study drug with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
          </group>
          <group group_id="O2">
            <title>AMG 529 21 mg SC</title>
            <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
          </group>
          <group group_id="O3">
            <title>AMG 529 70 mg SC</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>AMG 529 210 mg SC</title>
            <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O5">
            <title>AMG 529 420 mg SC</title>
            <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O6">
            <title>AMG 529 700 mg SC</title>
            <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
          </group>
          <group group_id="O7">
            <title>AMG 529 70 mg IV</title>
            <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides Concentration Over Time</title>
          <population>Randomized participants who received study drug with available data at each time point.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2292" spread="0.5080"/>
                    <measurement group_id="O2" value="1.1100" spread="0.5588"/>
                    <measurement group_id="O3" value="1.0050" spread="0.5478"/>
                    <measurement group_id="O4" value="1.3750" spread="0.9770"/>
                    <measurement group_id="O5" value="1.0533" spread="0.3525"/>
                    <measurement group_id="O6" value="1.5067" spread="1.0848"/>
                    <measurement group_id="O7" value="0.8317" spread="0.3036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0942" spread="0.2880"/>
                    <measurement group_id="O2" value="-0.1283" spread="0.1379"/>
                    <measurement group_id="O3" value="-0.0633" spread="0.2366"/>
                    <measurement group_id="O4" value="-0.0183" spread="0.3725"/>
                    <measurement group_id="O5" value="-0.1833" spread="0.0993"/>
                    <measurement group_id="O6" value="-0.5600" spread="0.6615"/>
                    <measurement group_id="O7" value="0.0750" spread="0.1244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0525" spread="0.3015"/>
                    <measurement group_id="O2" value="-0.0450" spread="0.1148"/>
                    <measurement group_id="O3" value="-0.0583" spread="0.1932"/>
                    <measurement group_id="O4" value="0.4580" spread="1.2469"/>
                    <measurement group_id="O5" value="-0.2900" spread="0.2521"/>
                    <measurement group_id="O6" value="-0.5783" spread="0.5958"/>
                    <measurement group_id="O7" value="0.3133" spread="0.3102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0975" spread="0.3470"/>
                    <measurement group_id="O2" value="0.2040" spread="0.7577"/>
                    <measurement group_id="O3" value="0.1400" spread="0.4963"/>
                    <measurement group_id="O4" value="0.1840" spread="0.4797"/>
                    <measurement group_id="O5" value="-0.1167" spread="0.4131"/>
                    <measurement group_id="O6" value="-0.5925" spread="1.0357"/>
                    <measurement group_id="O7" value="0.3320" spread="0.5496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0475" spread="0.5965"/>
                    <measurement group_id="O2" value="0.0920" spread="0.2212"/>
                    <measurement group_id="O3" value="0.5800" spread="0.6549"/>
                    <measurement group_id="O4" value="0.1780" spread="0.4043"/>
                    <measurement group_id="O5" value="0.2183" spread="0.2193"/>
                    <measurement group_id="O6" value="-0.4360" spread="0.9239"/>
                    <measurement group_id="O7" value="0.3340" spread="0.4185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0991" spread="0.4538"/>
                    <measurement group_id="O2" value="0.2320" spread="0.3214"/>
                    <measurement group_id="O3" value="0.5533" spread="0.7672"/>
                    <measurement group_id="O4" value="0.2600" spread="0.5742"/>
                    <measurement group_id="O5" value="0.0533" spread="0.4320"/>
                    <measurement group_id="O6" value="-0.0360" spread="0.5330"/>
                    <measurement group_id="O7" value="0.2220" spread="0.1580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4580" spread="0.5334"/>
                    <measurement group_id="O4" value="0.4900" spread="0.7883"/>
                    <measurement group_id="O5" value="0.0533" spread="0.3663"/>
                    <measurement group_id="O6" value="-0.3283" spread="0.5669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose up to 30 days for participants assigned to the 21 mg or 70 mg dose cohorts and up to 57 days for participants assigned to the 210 mg, 420 mg, or 700 mg dose cohorts.</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received a single dose of matching placebo by either subcutaneous or intravenous injection.</description>
        </group>
        <group group_id="E2">
          <title>AMG 529 21 mg SC</title>
          <description>Participants received a single dose of 21 mg AMG 529 on study day 1 by subcutaneous (SC) injection.</description>
        </group>
        <group group_id="E3">
          <title>AMG 529 70 mg SC</title>
          <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="E4">
          <title>AMG 529 210 mg SC</title>
          <description>Participants received a single dose of 210 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="E5">
          <title>AMG 529 420 mg SC</title>
          <description>Participants received a single dose of 420 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="E6">
          <title>AMG 529 700 mg SC</title>
          <description>Participants received a single dose of 700 mg AMG 529 on study day 1 by subcutaneous injection.</description>
        </group>
        <group group_id="E7">
          <title>AMG 529 70 mg IV</title>
          <description>Participants received a single dose of 70 mg AMG 529 on study day 1 by intravenous (IV) injection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

